Information on EC 3.4.17.21 - Glutamate carboxypeptidase II

for references in articles please use BRENDA:EC3.4.17.21
Word Map on EC 3.4.17.21
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.4.17.21
-
RECOMMENDED NAME
GeneOntology No.
Glutamate carboxypeptidase II
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
release of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Alanine, aspartate and glutamate metabolism
-
-
Metabolic pathways
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
111070-04-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
beagle dog
-
-
Manually annotated by BRENDA team
cynomolgus monkey
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
C57/Bl mice
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
acute exposure to valproic acid, a drug used for bipolar disorder and epilepsy and a known histone deacetylase inhibitor, for 4-6 h increases the glutamate carboxypeptidase II protein level in human astrocyte U-87MG cells but does not have a similar effect after 12-24 h exposure. Valproic acid does not affect the glutamate carboxypeptidase II mRNA expression, but decrease in glutamate carboxypeptidase II protein level by cycloheximide treatment is blocked by valproic acid. The valproic acid-induced increase of glutamate carboxypeptidase II protein level may be dependent on the ubiquitin/proteasome pathway. Valproic acid increases the acetylation of glutamate carboxypeptidase II protein at the lysine residues and facilitates a decrease of the poly-ubiquitinated glutamate carboxypeptidase II level. Similarly, M344, a specific histone deacetylase 1/6 inhibitor, also increases the glutamate carboxypeptidase II protein level
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
folyl-(gamma-L-glutamic acid)2 + H2O
folyl-gamma-L-glutamic acid + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-(gamma-L-glutamic acid)3 + H2O
folyl-(gamma-L-glutamic acid)2 + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-(gamma-L-glutamic acid)4 + H2O
folyl-(gamma-L-glutamic acid)3 + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-gamma-L-glutamic acid + H2O
folate + L-glutamate
show the reaction diagram
-
-
-
-
?
folyl-poly-gamma-glutamate + H2O
?
show the reaction diagram
-
cleavage of the C-terminal glutamate
-
-
?
gamma-L-Glu-L-Glu + H2O
L-Glu + L-Glu
show the reaction diagram
-
-
-
-
-
L-Asp-L-Glu + H2O
L-Asp + L-Glu
show the reaction diagram
-
-
-
-
-
L-Glu-L-Glu + H2O
L-Glu + L-Glu
show the reaction diagram
-
-
-
-
-
methotrexate triglutamate + H2O
L-Glu + methotrexate
show the reaction diagram
-
-
-
-
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
show the reaction diagram
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
?
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
N-Acetyl-L-Asp + L-Glu
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
N-[4-(phenylazo)-benzoyl]-L-glutamyl-gamma-L-glutamic acid + H2O
?
show the reaction diagram
-
-
-
-
?
poly-gamma-glutamate folate + H2O
?
show the reaction diagram
poly-gamma-Glutamylfolate + H2O
L-Glu + gamma-glutamylfolate
show the reaction diagram
-
-
removes sequentially gamma-linked glutamates
-
pteroylpentaglutamate + H2O
L-Glu + pteroylglutamate
show the reaction diagram
-
-
-
-
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
folyl-poly-gamma-glutamate + H2O
?
show the reaction diagram
-
cleavage of the C-terminal glutamate
-
-
?
N-acetyl-alpha L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
-
-
-
-
?
N-acetyl-alpha-L-aspartyl-L-glutamate + H2O
N-acetyl-alpha-L-aspartate + L-glutamate
show the reaction diagram
N-acetyl-Asp-Glu + H2O
N-acetyl-Asp + Glu
show the reaction diagram
N-Acetyl-L-Asp-L-Glu + H2O
?
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
L-glutamate + N-acetyl-L-aspartate
show the reaction diagram
N-acetyl-L-aspartyl-L-glutamate + H2O
N-acetyl-L-aspartate + L-glutamate
show the reaction diagram
poly-gamma-glutamate folate + H2O
?
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Br-
-
2 mM, activation
Cl-
-
2 mM, activation
F-
-
100 mM, 20% of the activity compared to Cl-
I-
-
2 mM, activation
K+
-
extracellularly applied K+ increases the enzyme activity in vivo in glial cells and the ventral nerve cord
Mg2+
-
activation
Mn2+
-
activation
NO3-
-
2 mM , activation
Sr2+
-
activation
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
the inhibitor has the ability to reduce the perception of inflammatory pain
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
-
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
-
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
EPE, a phosphapeptide transition state analog of glutamyl-glutamate
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
-
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(R)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
-
DCMC
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
-
DCFBC
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
-
DCIBzL
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
DCIT
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1072, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(S)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
(S)-alpha-ethylglutamate
-
specific group II metabotropic glutamate receptor antagonist, in vivo activity
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
-
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
-
(t-Bu)Cys-PSI[C-O]-Glu
-
IC50: 29 nM
(Z)-N-(N-Acetyldehydroaspartyl)-L-Glu
-
-
1,10-phenanthroline
-
1 mM, 90% inhibition
2-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 1700 nM
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
-
IC50: 2200 nM
2-(3-carboxybenyl)succinic acid
-
IC50: 0.015 mM
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
-
IC50: 1800 nM
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
-
IC50: 508 nM
2-(3-mercaptopropyl)-pentanedioic acid
2-(3-mercaptopropyl)pentanedioic acid
2-(3-sulfanylpropyl)pentanedioic acid
-
i.e. GPI-5693, attenuates cocaine-induced conditioned place preference
2-(phosphonomethyl) pentanedioic acid
-
inhibitor completely blocks N-acetylaspartylglutamate cleavage activity but not Amyloid-beta degradation
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
-
IC50: 175 nM
2-(phosphonomethyl)-pentanedioic acid
2-(phosphonomethyl)hexanedioic acid
-
IC50: 185 nM
2-(phosphonomethyl)hexanoic acid
-
IC50: 185 nM
2-(phosphonomethyl)pentanedioic acid
2-(Phosphonomethyl)pentanoate
-
-
2-(phosphonomethyl)succinic acid
-
IC50: 2200 nM
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 10 nM
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
i.e. quisqualic acid, a glutamate-like inhibitor of GCPIII and GCPII
2-benzyl-3-phosphonopropanoic acid
-
IC50: 548 nM
2-benzyl-5-mercaptopentanoic acid
-
IC50: 1400 nM
2-oxoglutarate
-
0.1 mM, 46% inhibition
2-phosphonomethyl-pentanedoic acid
-
2-PMPA
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
-
IC50: 3 nM
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 0.5 nM
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1 nM
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1.5 nM
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 156 nM
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 49 nM
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 143 nM
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 64 nM
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 4 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50 59 nM
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 230 nM
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 90 nM
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 68 nM
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-treated animals
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 2930 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 16 nM
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 59 nM
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 55 nM
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 95 nM
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
-
IC50: 3 nM
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
-
IC50: 14 nM
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
-
IC50: 640 nM
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
-
IC50: 0.015 mM
3-(2-carboxy-3-phosphonopropyl)benzoic acid
-
IC50: 120 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 15 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
-
IC50: 2700 nM
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
-
prodrug of inhibitor 2-(3-mercaptopropyl)pentanedioic acid
3-(3-mercaptopropyl)pentanedioic acid
-
presynaptic action of enzyme inhibition, enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
-
IC50: 730 nM
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
-
IC50: 32 nM
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
-
IC50: 2400 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
4-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 63 nM
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
-
IC50: 508 nM
4-cyano-2-(phosphonomethyl)butanoic acid
-
IC50: 335 nM
4-phenyl-2-(phosphonomethyl)butanoic acid
-
IC50: 199 nM
5-oxoheptane-1,3,7-tricarboxylic acid
-
0.1 mM, 35% inhibition
5-oxononane-1,3,7,9-tetracarboxylic acid
-
inhibitor possesses mGluR3 agonist activity
Ala-Glu
-
0.0061 mM, 50% inhibition
Asp-Ala
-
0.1 mM, 26% inhibition
Asp-Asp
-
0.1 mM, 42% inhibition
Asp-Glu
Asp-Phe
-
0.1 mM, 22% inhibition
Asp-PSI[C-O-S]-Glu
-
IC50: 0.0461 mM
Asp-PSI[C-O]-Asp
-
IC50: 0.0038 mM
Asp-PSI[S]-Asp
-
0.1 mM, 42% inhibition
aspartate
-
0.1 mM, 42% inhibition
bestatin
-
0.29 mM, 79% inhibition
Cys-PSI[C-O-S]-Glu
-
IC50: 6.9 nM
cysteate
-
0.1 mM, 40% inhibition
cysteine sulfinate
-
0.1 mM, 42% inhibition
D-Glu-D-Glu
-
0.1 mM, 50% inhibition
D-Glu-PSI[C-O]-D-Glu
-
0.1 mM, 67% inhibition
D-Glu-PSI[C-O]-Glu
-
0.001 mM, 25% inhibition
diazabicycloalkane
-
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
-
-
dithiothreitol
-
1 mM, 94.8% inhibition
DUPA
-
enzyme active site binding structure, docking and modelling, detailed overview
gamma-Glu-Glu
Glu-Asp
-
0.1 mM, 27% inhibition
Glu-Glu
Glu-Glu-Glu
Glu-PSI[C-O-C-O]-Glu
-
0.001 mM, 9% inhibition
Glu-PSI[C-O]-Glu
-
IC50: 47 nM
glutathione
-
i.e. gamma-Glu-Cys-Gly, 0.019 mM, 50% inhibition
Gly-Glu
Gly-Gly-Glu
-
0.00098 mM, 50% inhibition
Gly-PSI[C-O-S]-Glu
-
0.001 mM, 46% inhibition
GPI 5693
-
i.e. (R,S)-2-(3-mercaptopropyl)-pentanedioic acid or 2-MPPA, pharmacokinetics and safety of the NAALADase-inhibitor and its effects on the central nervous system after application in vivo, overview
GPI-16476
-
enantiomer of GPI-5693
GPI-16477
-
enantiomer of GPI-5693
GPI-18431
-
enzyme active site binding structure, docking and modelling, detailed overview
GPI-5693
-
-
GPI5232
Ibotenate
-
0.1 mM, 45% inhibition
iodoacetate
-
1 mM, 38% inhibition
L-2-Amino-4-phosphonobutanoate
-
0.1 mM, 37% inhibition
L-Glu
LY341495
-
-
MOPS
-
-
N-(3,4-Dicarboxybutanoyl)glutamic acid
-
-
N-(Dicarboxymethyl)acetylglutaminic acid
-
-
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
-
-
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 3D7H
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC3
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC2
N-Acetyl-Asp-Gln
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Glu-Asp
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Ser-Gly
-
0.1 mM, 37% inhibition
N-Acetyl-beta-L-Asp-L-Glu
N-Acetyl-Glu-Asp
-
0.036 mM, 50% inhibition
N-Acetyl-Glu-Glu
-
0.00031 mM, 50% inhibition
N-acetyl-L-Asp
-
0.1 mM, 38% inhibition
N-Acetyl-L-Asp-L-Glu
-
0.00054 mM, 50% inhibition
N-acetyl-L-Glu
-
0.058 mM, 50% inhibition
N-Fumaryl-L-Glu
-
-
N-Succinyl-L-Glu
-
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
Phe-Glu
-
0.077 mM, 50% inhibition
pteroylglutamic acid
-
-
puromycin
-
0.5 mM, 55% inhibition
pyroglutamate
-
0.1 mM, 27% inhibition
pyropheophorbide-a conjugate
-
i.e. Ppa-2 conjugate, non-specificity of unconjugated Ppa, conjugation of a peptidomimetic inhibitor of PSMA to the porphyrinic PS, pyropheophorbide-a gives
quinolinate
-
0.1 mM, 41% inhibition
Quisqualic acid
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
-
-
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
-
phosphoramidate
Serine O-sulfate
-
0.042 mM, 50% inhibition
t-BuNHC(O)-Glu
-
0.001 mM, 10% inhibition
Tyr-Glu
-
0.1 mM, 45% inhibition
VA-033
Val-Glu-Glu
-
0.036 mM, 50% inhibition
ZJ-43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid, the inhibitor enhances extracellular NAAG levels and reduces extracellular levels of amino acids neurotransmitter following traumatic brain injury in vivo
ZJ43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
[HO2C(CH2)2CH(CO2H)CH2]2P(O)(OH)
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
dynorphin A
-
activates glutamate production in the spinal cord
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000066 - 0.000334
N-acetyl-alpha-L-aspartyl-L-glutamate
130
N-acetyl-Asp-Glu
-
pH 7.4, 37°C
0.00014 - 540
N-Acetyl-L-Asp-L-Glu
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4
N-acetyl-Asp-Glu
-
pH 7.4, 37°C
1
N-acetyl-L-aspartyl-L-glutamate
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000008
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.000003
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.000012
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000009
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000149
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37°C
0.000335
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000059
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
pH 7.4, 37°C
0.0000053
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.002711
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000104
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.00109
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000719
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.00639
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.0146
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
pH 7.4, 37°C
0.00111
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
pH 7.4, 37°C
0.000095 - 0.0000953
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
0.000392
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
pH 7.4, 37°C; pH 7.4, 37°C, recombinant enzyme
0.00129
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000014 - 0.0000144
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
0.00111
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000129 - 0.0000346
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
0.001285
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37°C
0.001109
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
pH 7.4, 37°C
0.004388
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
pH 7.4, 37°C
0.0000015
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
-
0.00000024
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
0.0000046
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
-
0.000003
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000012
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000009
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000053
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.000335
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.00271
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000059
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37°C, recombinant enzyme
0.0000021
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
pH 7.4, 37°C; pH 7.4, 37°C, recombinant enzyme
0.000008
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
pH 7.4, 37°C, recombinant enzyme
0.00443 - 0.004434
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
1
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
above, pH 7.4, 37°C, recombinant enzyme
0.000015
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
pH 7.4, 37°C, recombinant enzyme
0.00439
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
pH 7.4, 37°C, recombinant enzyme
0.000939
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
pH 7.4, 37°C; pH 7.4, 37°C, recombinant enzyme
0.00003
2-(3-mercaptopropyl)-pentanedioic acid
-
-
0.0000002 - 0.0000014
2-(phosphonomethyl)-pentanedioic acid
0.0000002 - 0.0000014
2-(phosphonomethyl)pentanedioic acid
0.00023 - 0.00102
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
0.061
Ala-Glu
-
-
0.0024
Asp-Glu
-
-
0.1
D-Glu-D-Glu
-
-
0.000008
DUPA
-
-
0.095
gamma-Glu-Glu
-
-
0.00075
Glu-Glu
-
-
0.062
Glu-Glu-Glu
-
-
0.019
glutathione
-
i.e. gamma-Glu-Cys-Gly
0.008
Gly-Glu
-
-
0.00098
Gly-Gly-Glu
-
-
0.00003
GPI-18431
-
-
0.27 - 0.428
L-Glu
0.00000001
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
-
pH not specified in the publication, temperature not specified in the publication
0.0000053
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
pH not specified in the publication, temperature not specified in the publication
0.0000053
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
-
pH not specified in the publication, temperature not specified in the publication
0.036
N-Acetyl-Glu-Asp
-
-
0.00031
N-Acetyl-Glu-Glu
-
-
0.00054
N-Acetyl-L-Asp-L-Glu
-
-
0.058
N-acetyl-L-Glu
-
-
0.0000149
N-[[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]carbamoyl]-L-glutamic acid
-
pH 7.4, 37°C
0.077
Phe-Glu
-
-
0.042
Serine O-sulfate
-
-
0.036
Val-Glu-Glu
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0000002
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
Homo sapiens;
-
-
0.0003
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens;
-
-
0.0000007
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
Homo sapiens;
-
-
0.0000001
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens;
-
-
0.0000008
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens;
-
-
0.000004
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens;
-
-
0.000004
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
Homo sapiens;
-
-
0.000018
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
Homo sapiens;
-
-
0.0014
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens;
-
40fold less potent than the S-isomer, IC50: 0.0014 mM
0.00003
(R)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens;
-
less potent than the S-isomer, IC50: 0.000030 mM
0.000017
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000014
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.00000006
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.0000005
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000245
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000037
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens;
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000004
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000003
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000277
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000443
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens;
-
-
0.000012
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000043
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000002
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.0012
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000022
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
Homo sapiens;
-
-
0.00001
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
Homo sapiens;
-
-
0.000154
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
Homo sapiens;
-
-
0.00296
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000498
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.003
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
Homo sapiens;
-
-
0.000034
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
Homo sapiens;
-
40fold more potent than the R-isomer, IC50: 0.000034 mM
0.0000001
(S)-2-(phosphonomethyl)-pentanedioic acid
Homo sapiens;
-
more potent than the R-isomer, IC50: 0.0000001 mM
0.000029
(t-Bu)Cys-PSI[C-O]-Glu
Rattus norvegicus;
-
IC50: 29 nM
0.0017
2-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens;
-
IC50: 1700 nM
0.0022
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
Homo sapiens;
-
IC50: 2200 nM
0.015
2-(3-carboxybenyl)succinic acid
Homo sapiens;
-
IC50: 0.015 mM
0.0018
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
Homo sapiens;
-
IC50: 1800 nM
0.000508
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
Rattus norvegicus;
-
IC50: 508 nM
0.00009
2-(3-mercaptopropyl)-pentanedioic acid
Homo sapiens;
-
i.e. 2-MPPA, IC50: 90 nM
0.00009
2-(3-mercaptopropyl)pentanedioic acid
Rattus norvegicus;
-
IC50: 90 nM. Orally bioavailable in rats
0.000175
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
Rattus norvegicus;
-
IC50: 175 nM
0.00000674 - 0.000094
2-(phosphonomethyl)-pentanedioic acid
0.000185
2-(phosphonomethyl)hexanedioic acid
Rattus norvegicus;
-
IC50: 185 nM
0.000185
2-(phosphonomethyl)hexanoic acid
Rattus norvegicus;
-
IC50: 185 nM
0.0000003 - 0.0000051
2-(phosphonomethyl)pentanedioic acid
0.0022
2-(phosphonomethyl)succinic acid
Rattus norvegicus;
-
IC50: 2200 nM
0.000055
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus;
-
IC50: 55 nM
0.000055
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus;
-
IC50: 55 nM
0.00001
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
Rattus norvegicus;
-
IC50: 10 nM
0.000548
2-benzyl-3-phosphonopropanoic acid
Rattus norvegicus;
-
IC50: 548 nM
0.0014
2-benzyl-5-mercaptopentanoic acid
Homo sapiens;
-
IC50: 1400 nM
0.000003
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 3 nM
0.0000005
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 0.5 nM
0.000002
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 2 nM
0.000002
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 2 nM
0.000001
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 1 nM
0.0000015
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 1.5 nM
0.000156
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 156 nM
0.000049
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 49 nM
0.000143
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 143 nM
0.00007
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 70 nM
0.000064
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 64 nM
0.000004
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 4 nM
0.000053 - 0.00007
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
0.000149 - 0.00015
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
0.000059
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50 59 nM
0.00023
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 230 nM
0.00009
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 90 nM
0.000068
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 68 nM
0.000082
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-
0.00293
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 2930 nM
0.00036 - 0.00056
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
0.000016
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 16 nM
0.000059
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 59 nM
0.000055
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 55 nM
0.000095
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
Rattus norvegicus;
-
IC50: 95 nM
0.000003
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
Rattus norvegicus;
-
IC50: 3 nM
0.000014
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
Homo sapiens;
-
IC50: 14 nM
0.00064
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
Homo sapiens;
-
IC50: 640 nM
0.015
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
Homo sapiens;
-
IC50: 0.015 mM
0.00012
3-(2-carboxy-3-phosphonopropyl)benzoic acid
Homo sapiens;
-
IC50: 120 nM
0.000015
3-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens;
-
IC50: 15 nM
0.0027
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
Homo sapiens;
-
IC50: 2700 nM
0.02
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
Homo sapiens;
-
IC50: 0.02 mM
0.02
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
Homo sapiens;
-
IC50: 0.02 mM
0.002
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
Rattus norvegicus;
-
pH not specified in the publication, temperature not specified in the publication
0.00073
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
Homo sapiens;
-
IC50: 730 nM
0.000032
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
Homo sapiens;
-
IC50: 32 nM
0.0024
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
Homo sapiens;
-
IC50: 2400 nM
0.000063
4-(2-carboxy-5-mercaptopentyl)benzoic acid
Homo sapiens;
-
IC50: 63 nM
0.000508
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
Rattus norvegicus;
-
IC50: 508 nM
0.000335
4-cyano-2-(phosphonomethyl)butanoic acid
Rattus norvegicus;
-
IC50: 335 nM
0.000199
4-phenyl-2-(phosphonomethyl)butanoic acid
Rattus norvegicus;
-
IC50: 199 nM
0.0461
Asp-PSI[C-O-S]-Glu
Rattus norvegicus;
-
IC50: 0.0461 mM
0.0038
Asp-PSI[C-O]-Asp
Rattus norvegicus;
-
IC50: 0.0038 mM
0.0000069
Cys-PSI[C-O-S]-Glu
Rattus norvegicus;
-
IC50: 6.9 nM
0.000002
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
Homo sapiens;
-
-
0.000047
Glu-PSI[C-O]-Glu
Rattus norvegicus;
-
IC50: 47 nM
0.000007
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
Homo sapiens;
-
-
0.000008
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
Homo sapiens;
-
-
0.000102
pyropheophorbide-a conjugate
Homo sapiens;
-
pH 7.4, 37°C
0.000014
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens;
-
-
0.00000068
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
Homo sapiens;
-
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.000000054 - 0.000000148
-
-
0.0000036
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
5
-
second optimum at pH 8
7.5
assay at
7.7
-
assay at, recombinant enzyme
8
-
second optimum at pH 5
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6 - 7.4
-
more than 50% of maximal activity in this range
additional information
pH profile
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25 - 80
-
more than 50% of maximal activity in this range
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
quantitative expression analysis
Manually annotated by BRENDA team
-
cortical cells dissociated in cell culture
Manually annotated by BRENDA team
-
ventricular, lumbar, and subarachnoid
Manually annotated by BRENDA team
-
primary cancer
Manually annotated by BRENDA team
-
dorsal root ganglia
Manually annotated by BRENDA team
-
PSMA is expressed in the neovasculature of multiple nonprostatic solid tumors, it shows a unique expression pattern limited to tumor-associated endothelial cells. Expression in liver metastasis from colorectal cancers and lymph node metastasis from colorectal cancers
Manually annotated by BRENDA team
GCPIII
Manually annotated by BRENDA team
GCPIII
Manually annotated by BRENDA team
-
very low enzyme expression level
Manually annotated by BRENDA team
-
prostate cancer cell line
Manually annotated by BRENDA team
-
high expression level
Manually annotated by BRENDA team
-
higher level in patients with prostrate cancer, lower levels in healthy male donors
Manually annotated by BRENDA team
GCPIII
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
associated with
Manually annotated by BRENDA team
-
synaptoneurosome
-
Manually annotated by BRENDA team
additional information
-
Vinca alkaloids destabilize the microtubules leading to basolateral expression of the enzyme and its integration into the basolateral membrane
-
Manually annotated by BRENDA team
PDB
SCOP
CATH
UNIPROT
ORGANISM
Homo sapiens;